Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaNovel treatment targets BTK through multi-immune ...

Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...

Mondego Bio Lda has selected protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitor ZE00-0388 as its lead clinical candidate. The company is targeting initiation of a first-in-human phase ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

Takeda (TAK) stock spikes as the company announces success in two Phase 3 trials designed to evaluate its oral plaque psoriasis drug, zasocitinib. Read more here.

Takeda ( TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib ...

Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...

Ascentage Pharma's first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in ...

Healio spoke with Matthew S. Davids, MD, about a recent study comparing continuous treatment with a Bruton tyrosine kinase inhibitor with time-limited venetoclax-based therapy for chronic lymphocytic ...

A new study presents robust evidence on the role of lysophosphatidylcholines (LPCs) in the onset of Alzheimer's disease.